다만 한국투자신탁운용의 반대에도 불구하고 하이트진로와 삼진제약이 상정한 안건은 모두 원안대로 모두 통과됐다.
However, despite opposition from Korea Investment Trust Management, all agenda items proposed by Hite Jinro and Samjin Pharmaceutical were passed as originally proposed.